Latest filing published 23 Jun 2021 for Agios Pharmaceuticals, INC., €77k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Carman Alenson: trading record in brief
This profile gathers the share dealings of Carman Alenson in Agios Pharmaceuticals, Inc. The record holds 30 filings, for trades running from 12 January 2018 to 21 June 2021.
No open-market purchase appears, only 12 sales worth €671k. The rest of the record consists of 6 share grants and 12 option exercises. 2021 to date brings no purchases and 3 sales.
The newest entry dates from 23 June 2021: an open-market sale of €92k, in Agios Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Carman Alenson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,777 shares@ US$51.51100.0% of flowCommon stockSEC:0001439222-21-000060:0
1 of 1 declaration
